Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;16(9):1296-1305.
doi: 10.2174/1570159X15666170808120633.

Neuroprotective Role of Agmatine in Neurological Diseases

Affiliations
Review

Neuroprotective Role of Agmatine in Neurological Diseases

Weilin Xu et al. Curr Neuropharmacol. 2018.

Abstract

Background: Neurological diseases have always been one of the leading cause of mobility and mortality world-widely. However, it is still lacking efficient agents. Agmatine, an endogenous polyamine, exerts its diverse biological characteristics and therapeutic potential in varied aspects.

Methods: This review would focus on the neuroprotective actions of agmatine and its potential mechanisms in the setting of neurological diseases.

Results: Numerous studies had demonstrated the neuroprotective effect of agmatine in varied types of neurological diseases, including acute attack (stroke and trauma brain injury) and chronic neurodegenerative diseases (Parkinson's disease, Alzheimer's disease). The potential mechanism of agmatine induced neuroprotection includes anti-oxidation, anti-apoptosis, anti-inflammation, brain blood barrier (BBB) protection and brain edema prevention.

Conclusions: The safety and low incidence of adverse effects indicate the vast potential therapeutic value of agmatine in the treatment of neurological diseases. However, most of the available studies relate to the agmatine are conducted in experimental models, more clinical trials are needed before the agmatine could be extensively clinically used.

Keywords: Agmatine; chronic neurodegenerative diseases; mechanism; neurological diseases; neuroprotective effect; stroke..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Overview of the neuroprotective effects of agmatine.
Fig. (2)
Fig. (2)
Chemical structure of agmatine (Tayfun I. Uzbay et al., 2012.).

Similar articles

Cited by

References

    1. Wu H., Niu H., Shao A., Wu C., Brandon J. Astaxanthin as a potential neuroprotective agent for neurological diseases. Mar. Drugs. 2015;13:5750–5766. - PMC - PubMed
    1. Yi B.R., Kim S.U., Choi K.C. Development and application of neural stem cells for treating various human neurological diseases in animal models. Lab. Anim. Res. 2013;29(3):131–137. [http:// dx.doi.org/10.5625/lar.2013.29.3.131]. [PMID: 24106507]. - PMC - PubMed
    1. Xu X.H., Zhong Z. Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol. Sin. 2013;34(6):755–764. [http://dx.doi.org/ 10.1038/aps.2013.63]. [PMID: 23685955]. - PMC - PubMed
    1. Kim J.H., Yenari M.A., Giffard R.G., Cho S.W., Park K.A., Lee J.E. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp. Neurol. 2004;189(1):122–130. [http:// dx.doi.org/10.1016/j.expneurol.2004.05.029]. [PMID: 15296842]. - PubMed
    1. Gilad G.M., Gilad V.H., Finberg J.P., Rabey J.M.

MeSH terms

LinkOut - more resources